Trends in Usage of Alternative Antiplatelet Therapy After Stroke and Transient Ischemic Attack
Key result
Prescription of clopidogrel-aspirin after stroke or TIA decreased sharply from 31.5% to 12.8% (P<0.0001) following the MATCH trial, while use of clopidogrel alone and dipyridamole-aspirin increased.
Population
18,020 patients admitted with ischemic stroke or transient ischemic attack across 85 US hospitals between…
Design
Cohort
Follow-up
at discharge
Authors
Discussion
Loading...
Member takes
Implication
Prescribing patterns shifted promptly after MATCH; supports clinician responsiveness to trial evidence yet leaves generalizability to outcomes open.
Study Design
Type
Observational (n=18,020)
Multicenter
Yes
Structured PICO
P
Population
18,020 patients admitted with ischemic stroke or transient ischemic attack across 85 US hospitals between 2001 and 2005.
E
Exposure
Prescription of antiplatelet medications (clopidogrel, dipyridamole, aspirin) at discharge
O
Outcome
Rates of antiplatelet medication usage at discharge over time
Main Result
p-value: p=<0.0001
Clinical practice patterns for antiplatelet therapy after stroke or TIA rapidly adapted to new clinical trial evidence regarding efficacy and bleeding risks.
Cite This Study
Hills et al. (2008) conducted an observational in Ischemic stroke or transient ischemic attack (n=18,020). Alternative antiplatelet therapy was evaluated on Rates of antiplatelet medication usage at discharge over time (p=<0.0001). Prescription of clopidogrel-aspirin after stroke or TIA decreased sharply from 31.5% to 12.8% (P<0.0001) following the MATCH trial, while use of clopidogrel alone and dipyridamole-aspirin increased.